The makers of Eliquis may have tapped a way of stopping life-threatening episodes of internal bleeding, an injury that has allegedly plagued a number of Xarelto plaintiffs who have filed cases over the blood thinner.
Portola Pharmaceuticals, the company that manufactures Eliquis, publicly stated on October 1 that primary and secondary endpoints in a Phase 3 clinical trial had been reached, and that Andexanet Alfa could likely be a reversal agent for internal bleeding episodes. The progress in this study suggests that Eliquis may soon have a readily available antidote.
Interestingly, Eliquis is the most recent new-generation blood thinner to gain approval from the U.S. Food and Drug Administration (FDA), following Pradaxa and Xarelto. These medications also carry internal bleeding risks, which may be fatal since there is no known reversal agent. Eliquis was introduced by Pfizer and Bristol-Myers Squibb in 2012.
That same year, an investigation of the FDA’s adverse event reports pulled up more than 4,000 complaints mentioning side effects alleged in Xarelto lawsuit claims. 151 fatalities were also recorded, according to a report from the Institute of Safe Medicine Practices.
Xarelto is jointly marketed by Bayer HealthCare and the Johnson & Johnson subsidiary, Janssen Pharmaceuticals, and is used to prevent blood clots in patients with atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and reduce the risk of blood clots in patients who have recently undergone hip replacement surgeries.
Unfortunately for many, the use of this drug may lead to cerebral and gastrointestinal hemorrhaging, pulmonary embolism, deep vein thrombosis and even death, in a worst-case scenario. That’s why it’s imperative that anyone who may be experiencing the following symptoms contact their doctor immediately. If too much time passes, it may be too late.
Xarelto internal bleeding may manifest in black or tarry stool, blood in the urine, coughing or vomiting up blood, bleeding from the gums, or swelling and weakness in the extremities.
As the FDA continues to probe the safety of this blood thinner, court records indicate that lawsuits alleging Xarelto bleeding effects have already been filed.